Pharmacology of Induced Artificial Platelets in Regenerative Medicine: Beyond Transfusion

Induced pluripotent stem cell (iPSC)-derived artificial platelets offer a promising advancement in regenerative medicine by overcoming the limitations of platelet-rich plasma therapies, such as batch variability and inconsistent outcomes. These artificial platelets are produced under standardized, scalable conditions, ensuring precise control over their composition and function. Preclinical studies have shown their therapeutic efficacy in osteoarthritis models, and emerging clinical data indicate acceptable safety profiles. This shift from transfusion-focused applications to regenerative medicine necessitates new pharmacological characterization frameworks, highlighting the potential of iPSC-derived artificial platelets in providing consistent and effective regenerative therapies.